CliffBio
small molecule

ZOKINVY

LONAFARNIB

Loss of exclusivityJuly 2029latest FDA-listed patent expiry
CompanySentynl Therapeutics, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameZOKINVY
Active ingredientLONAFARNIB
Strength75MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2020
Marketing statusRX

Listed patents

PatentExpiresType
7838531July 2029use U-3070

Regulatory exclusivity

CodeExpires
ODE-324November 2027

More from Sentynl Therapeutics, Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ZOKINVY patent cliff — loss of exclusivity July 2029 | CliffBio